Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Fokus Mining Intersects 10 Metres Grading 10.06 G/T At The Galloway Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

GeoVax Labs Inc GOVX

Healthcare Biotechnology
GeoVax Labs, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using its platforms. Its product pipeline includes ongoing human clinical trials for a COVID-19 and a gene-directed therapy against advanced head and neck cancers. It is developing a number of vaccines and immunotherapies for prevention or treatment of infectious diseases and cancers. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02, GEO-EM01, GEO-LM01 and GEO-MM02. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations. Its research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg and Lassa) and Zika virus, as well as immunotherapies for multiple solid tumors. Its wholly owned subsidiary is GeoVax, Inc.


NDAQ:GOVX - Post by User

GeoVax Labs Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(57)
•••
Post by Iseneschalon Aug 19, 2021 11:23am
148 Views
Post# 33730378

GOVX

GOVXWO2021163622 VACCINES AND USES THEREOF TO INDUCE AN IMMUNE RESPONSE TO SARS-COV2 (wipo.int)
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities